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Abstract
Background: In type 1 von Willebrand Disease (VWD) patients, von Willebrand Factor (VWF) levels and bleeding symptoms
are highly variable. Recently, the association between genetic variations in STXBP5 and STX2 with VWF levels has been
discovered in the general population. We assessed the relationship between genetic variations in STXBP5 and STX2, VWF
levels, and bleeding phenotype in type 1 VWD patients.
Methods: In 158 patients diagnosed with type 1 VWD according to the current ISTH guidelines, we genotyped three
tagging-SNPs in STXBP5 and STX2 and analyzed their relationship with VWF:Ag levels and the severity of the bleeding
phenotype, as assessed by the Tosetto bleeding score.
Results: In STX2, rs7978987 was significantly associated with VWF:Ag levels (be`ta-coefficient (b) =20.04 IU/mL per allele,
[95%CI 20.07;20.001], p = 0.04) and VWF:CB activity (b=20.12 IU/mL per allele, [95%CI 20.17;20.06], p,0.0001). For
rs1039084 in STXBP5 a similar trend with VWF:Ag levels was observed: (b=20.03 IU/mL per allele [95% CI 20.06;0.003],
p = 0.07). In women, homozygous carriers of the minor alleles of both SNPs in STXBP5 had a significantly higher bleeding
score than homozygous carriers of the major alleles. (Rs1039084 p= 0.01 and rs9399599 p= 0.02).
Conclusions: Genetic variation in STX2 is associated with VWF:Ag levels in patients diagnosed with type 1 VWD. In addition,
genetic variation in STXBP5 is associated with bleeding phenotype in female VWD patients. Our findings may partly explain
the variable VWF levels and bleeding phenotype in type 1 VWD patients.
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Introduction
Von Willebrand factor is a multifunctional glycoprotein, which
is involved in platelet adhesion and subsequent platelet aggrega-
tion during primary haemostasis [1,2]. Low VWF levels are a
diagnostic criterion for Von Willebrand Disease (VWD), the most
common inherited bleeding disorder. VWD is classified as either a
quantitative deficiency of von Willebrand Factor (VWF) (type 1
and 3 VWD) or as a qualitative defect of VWF molecules (type 2
VWD). Furthermore, according to the current ISTH guidelines
diagnosis of VWD is based on clinical criteria, including a
mucocutaneous bleeding history and a family history of excessive
bleeding [3].
In type 1 VWD patients, who have reduced but functionally
normal VWF molecules, VWF levels are highly variable. Also, the
VWD phenotype penetrates incompletely leading to a variable
clinical presentation. To date, we can only explain part of the
variation in VWF levels and bleeding symptoms in these patients.
In recent years, genome-wide association studies have been
performed and have enabled us to investigate the genetic
component of common diseases and quantitative traits without a
prior biological hypothesis. In this way, novel genetic determinants
of VWF:Ag levels have been discovered: STXBP5, SCARA5,
STAB2, STX2, TC2N, and CLEC4M [4]. Our interest was
especially focussed on STXBP5 and STX2, because their
encoding proteins are suggested to be involved in WPB exocytosis
[5].
Syntaxin 2 (STX2) is a binding substrate for the Syntaxin
Binding Protein 5 (STXBP5) and is a member of the Soluble N-
ethylmaleimide-sensitive factor (NSF) Attachment protein Recep-
tor (SNARE) protein family. These proteins drive vesicle
exocytosis by fusion of granules and target membranes, a process
involved in the regulation of numerous secretory events [6].
STXBP5 and STX2 interact specifically with SNARE complex
proteins, such as SNAP23 and syntaxin-4. These proteins have
been shown to be involved in Weibel Palade Body (WPB)
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exocytosis, the well known mechanism for the secretion of VWF
molecules by endothelial cells [5].
Dysfunction of the WPB machinery is a likely contributor to the
variation in VWF:Ag levels in type 1 VWD patients. Also, since we
have recently confirmed the association between genetic variation
in STXBP5 and STX2 and VWF:Ag levels in young patients with a
first event of arterial thrombosis [7], we hypothesized that genetic
variation in STXBP5 and STX2 may also affect VWF:Ag levels in
patients diagnosed with type 1 VWD according to the current
ISTH guidelines. In addition, genetic variation in STXBP5 and
STX2 may, by regulating VWF:Ag levels, influence the incomplete
penetrance and the variable clinical presentation of type 1 VWD.
Therefore, we aimed to assess the relationship between genetic
variation in STXBP5 and STX2, VWF:Ag levels, and the bleeding
phenotype in patients previously diagnosed with type 1 VWD.
Methods
Study Population
In this study we included 158 patients, who were previously
diagnosed with type 1 VWD in the Erasmus University Medical
Center Rotterdam. The diagnosis of type 1 VWD was based on
clinical bleeding symptoms, a family history of bleeding, and
VWF:Ag levels or VWF:Rco activity #0.30 IU/mL, according to
the current ISTH guidelines [3].
Ethics Statement
The study was approved by the medical research board at
Erasmus University Medical Center and written informed consent
was obtained from all participants at inclusion.
Laboratory measurements
Blood was drawn by venipuncture in the antecubital vein using
Vacutainer system (Becton-Dickinson, Plymouth, UK). Blood for
coagulation measurements was collected in 3.2% trisodium citrate
(9:1 vol/vol). Citrated blood was centrifuged within 1 hour at
20006g for 10 min at 4uC. Plasma was additionally centrifuged at
14,0006g for 10 minutes at 4uC and stored in aliquots at 280uC.
For DNA isolation blood was collected in tubes containing
ethylene diaminetetraacetic acid (EDTA; Beckon Dickinson) and
genomic DNA was isolated according to standard salting-out
procedures and stored at 4uC for genetic analysis.
VWF:Ag was determined with an in-house ELISA with
polyclonal rabbit anti-human VWF antibodies and horseradish
peroxidase conjugated anti-human VWF antibodies (DakoCyto-
mation, Glostrup, Denmark) for catching and tagging, respective-
ly. For our analyses we used the lowest VWF:Ag level that was
ever measured in a patient (historical VWF:Ag measurement).
VWF collagen binding (VWF:CB) was measured with an in-
house ELISA using type I collagen (Sigma, St. Louis, USA) for
catching and horseradish peroxidase conjugated anti-human VWF
antibodies for tagging.
VWF:RCo was assayed with formalin-fixed platelets using a
PAP4 Model Aggregometer (Bio-Data Corp. Hatboro, Pennsylva-
nia) according to Macfarlane et al. [8].
Bleeding score
The Bleeding Score was used as previously described for
bleeding severity in type 1 VWD by Tosetto et al [9]. It
systematically evaluates bleeding symptoms, and accounts for both
the number and severity of the bleeding symptoms. Each patient
completed a questionnaire, which included the Bleeding Score
assessment tool. The severity and frequency of twelve items are
scored on a scale ranging from minus one to four points. Higher
scores reflect a more severe bleeding phenotype characterized by
more severe or more frequent bleeding. The total for all twelve
items result in a Bleeding Score (range 23 to 45).
Genotyping analysis
The STXBP5 gene spans 182 kbps and is located in the q24
region of chromosome 6. The STX2 gene spans 50 kbp and is
located in the q24.3 region of chromosome 12. Initially, we
obtained data from the International HapMap project (phase II
November 2008 http://www.hapmap.org) on the linkage disequi-
librium (LD) pattern and selected haplotype-tagging single-
nucleotide polymorphisms (ht-SNPs) using Haploview software
(version 3.11; www.broad.mit.edu/mpg/haploview/index/php).
For both genes blocks of haplotypes with a frequency of $3%
were defined in order to select ht-SNPs. We took potential
functionality into consideration by preferentially selecting non-
synonymous ht-SNPs or SNPs that are located in known
regulatory elements. We considered only SNPs that were present
in a Caucasian population. Of these ht-SNPs, three were
significantly associated with VWF:Ag levels in our previous study
among young patients with arterial thrombosis and healthy
controls [7]. Therefore, we selected and genotyped only these
three SNPs in STXBP5 (rs1039084 and rs9399599) and in STX2
(rs7978987) for our current study using Custom TaqMan
Genotyping Assays (Applied Biosystems, Foster City, CA, USA).
The polymorphisms in STXBP5, rs1039084 and rs9399599, are in
high linkage disequilibrium with rs9390459, which had the highest
genome wide significance level for VWF plasma levels in the meta-
analysis of the CHARGE consortium (D9=1.00, R2= 0.87 for
rs9399599 and D9=0.96, R2= 0.86 for rs1039084) (phase II
November 2008 http://www.hapmap.org). Also, rs7978987 in
STX2 had a highly significant P value of 3.82610211 in this meta-
analysis. Endpoint fluorescence was measured on the ABI
7900HT instrument (Applied Biosystems, Foster City, CA, USA)
and clustered according to genotype using SDS 2.1 software
(Applied Biosystems, Foster City, CA, USA). Genotyping was
successful for each SNP in on average 96% of all subjects.
Statistical analysis
Allele frequencies were calculated by genotype counting. For
each SNP the deviation from the Hardy-Weinberg equilibrium
was tested by means of a Chi-squared test with one degree of
freedom. VWF:Ag, VWF:RCo, and VWF:CB levels per genotype
of each SNP were assessed by analysis of covariance (ANCOVA)
adjusted for age and sex. Homozygous carriers of the VWF:Ag
increasing allele were used as reference category. In addition, to
analyze the trend across genotypes we performed linear regression
analysis on VWF measures using the genotypes of each SNP as a
continuous variable under the assumption of an additive genetic
model (i.e. alleles have no dominant or recessive effect). To
investigate the effect of ABO blood group on this association, the
latter analysis was additionally adjusted for blood group (O and
non-O).
The effect of genetic variation on the bleeding score has been
assessed by ANCOVA adjusted for the age at the time of
completing the questionnaire. Since the bleeding score differs
significantly between men and women, we stratified this analysis
by sex additionally.
Statistical analyses were performed with SPSS for Windows,
version 17.0 (SPSS Inc, Chicago, USA). A two-sided value of
p,0.05 was considered statistically significant.
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Results
Baseline characteristics
Baseline characteristics of the study population are displayed in
table 1. We included 158 subjects diagnosed with type 1 VWD,
who had a mean historical VWF:Ag level of 0.3560.13 IU/mL
(mean 6 standard deviation), VWF:CB of 0.2960.13 IU/mL,
and VWF:Rco of 0.2760.14 IU/mL. The mean age at inclusion
was 46.0616.8 years and 100 patients (63.3%) were female. Blood
group O was the most frequent among these patients (78.5%). The
allele frequency distributions of the genetic polymorphisms did not
deviate from the Hardy–Weinberg equilibrium.
Association between polymorphisms in STXBP5 and
STX2 and VWF:Ag levels
In STX2, rs7978987 (intron 9) was significantly associated with
VWF:Ag levels (beta-coefficient (b) =20.04 IU/mL per allele,
[95%CI 20.07;20.001], p= 0.04) and VWF:CB activity
(b=20.12 IU/mL per allele, [95%CI 20.17;20.06],
p,0.0001), also after adjustment for blood group (p= 0.04 for
VWF:Ag and p,0.0001 for VWF:CB) (table 2). Interestingly, the
frequency of the minor allele (MAF) of rs7978987, which
corresponded with higher VWF:Ag levels, was lower among our
patients with type 1 VWD (MAF=0.29) than reported by dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/) (MAF=0.38) and
in the meta-analysis of the CHARGE consortium (MAF=0.35)
[4].
For rs1039084 in STXBP5, which is a missense mutation that
encodes an amino acid substitution of asparagine into serine at
position 436 a similar trend with VWF:Ag levels was observed:
(b=20.03 IU/mL per allele [95% CI 20.06;0.003], p= 0.07)
(table 2). Rs9399599 in STXBP5, which is located in intron 25,
was not associated with VWF:Ag levels nor with VWF:CB, though
carriers of the minor allele had lower VWF:Ag levels and
VWF:CB activity as was also observed for rs1039084.
Rs1039084 and rs9399599 have a strong linkage disequilibrium
of D9=0.88 and R2= 0.71. Haplotype analysis showed that both
SNPs contribute to the variation in VWF:Ag levels (figure 1).
The VWF:RCo activity and VWF:CB activity showed similar
associations for both SNPs in STXBP5, although not statistically
significant (table 2).
Association between polymorphisms in STXBP5 and
STX2 and the bleeding phenotype
The mean bleeding score was 1268 in women (N=100) and
866 in men (N=58) (P = 0.001). In women, homozygous carriers
of the minor alleles of both SNPs in STXBP5 had a significantly
higher bleeding score than homozygous carriers of the major allele
(rs1039084: GG 962 versus AA 1562, p= 0.01 and rs9399599:
AA 962 versus TT 1461, p = 0.02) (figure 2). Rs7978987 in STX2
was not associated with the bleeding score.
Discussion
In the current study we have shown that genetic variation in
STX2 and to a lesser extent in STXBP5 contributes to VWF:Ag
Table 1. Baseline characteristics of the study population.
Type 1 VWD patients Males Females P value
(N=158) (N=58) (N=100)
Age (years) 46.0616.8 42.9619.4 47.8614.9 0.08
Female (%) 100 (63.3%) - -
Blood group O (%) 124 (78.5%) 46 (79.3%) 78 (78.0%) 0.85
Bleeding score (points) 1167 866 1267 0.001
VWF:Ag (IU/mL) 0.3560.13 0.3460.11 0.3660.14 0.38
VWF:CB (IU/mL) 0.2960.21 0.2860.16 0.3060.24 0.64
VWF:RCo (IU/mL) 0.2760.14 0.2660.11 0.2860.16 0.48
Summary statistics for continuous variables are presented as mean 6 standard deviation. Categorical data are summarized as percentages. Abbreviations used in this
table are VWF for Von Willebrand Factor and VWD for Von Willebrand Disease. The P value represents the difference between sexes for each variable.
doi:10.1371/journal.pone.0040624.t001
Table 2. VWF:Ag, VWF:RCo, and VWF:CB per genotype.
SNP# Gene N VWF:Ag VWF:RCo VWF:CB
(IU/mL) (IU/mL) (IU/mL)
rs1039084 STXBP5
GG 37 0.3860.02 0.3060.02 0.3360.04
AG 79 0.3560.02 0.2760.02 0.3160.03
AA 34 0.3360.02 0.2560.03 0.2560.04
p for trend 0.07 0.09 0.12
rs9399599 STXBP5
AA 36 0.3660.02 0.2860.02 0.3360.04
AT 76 0.3560.02 0.2760.02 0.2860.03
TT 39 0.3460.02 0.2560.02 0.3060.04
p for trend 0.40 0.31 0.62
rs7978987 STX2
AA 10 0.4060.04 0.2860.05 0.5360.07
AG 67 0.3760.02 0.2860.02 0.3260.03
GG 73 0.3360.02 0.2660.02 0.2460.03
p for trend 0.04 0.43 ,0.0001
VWF:Ag, VWF:Rco, and VWF:CB levels (mean 6 SE) per genotype of each SNP
(ANCOVA adjusted for age and sex). P for trend was calculated using linear
regression on VWF:Ag measures with additive genetic models. Abbreviations
used in this table are SNP for single nucleotide polymorphism, MAF for minor
allele frequency, and VWF for Von Willebrand Factor.
doi:10.1371/journal.pone.0040624.t002
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levels in patients diagnosed with type 1 VWD. In addition, we
demonstrate that in women with type 1 VWD genetic variation in
STXBP5 is associated with the bleeding phenotype.
We are the first to describe the association between genetic
variation in SNARE protein genes and VWF:Ag levels and
VWF:CB in patients previously diagnosed with type 1 VWD. In
our analysis we used historical levels, since we expect that the
lowest levels ever measured are the least influenced by external
factors, such as inflammation, hormones, and stress, and therefore
reflect a steady state situation.
SNPs in STXBP5 and STX2 have been previously identified in
the meta-analysis of the CHARGE consortium as determinants of
VWF levels in the general population. The effect sizes we obtained
were comparable with previous studies [4,7]. In our study, the
selected SNPs are the same or are in high linkage disequilibrium
with those identified in the CHARGE meta-analysis. Though the
selected SNPs in STXBP5 are in high LD (D9=0.88 and
Figure 1. Haplotype analysis for rs1039084 and rs9399599. Graph presents the coefficients with standard error per haplotype. Haplotype 1
was used as reference haplotype. NS =not significant.
doi:10.1371/journal.pone.0040624.g001
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R2= 0.71) the effect estimate of rs1039084 was slightly higher than
for rs9399599. Haplotype analysis showed that both SNPs have an
effect on VWF:Ag levels. It can be anticipated that since
rs1039084 is a non-synonymous SNP and rs9399599 is intronic,
rs1039084 may be the actual causal variant with a greater effect.
Interestingly, the frequency of the minor allele of rs7978987 that
was significantly associated with higher VWF:Ag levels, was much
lower in our type 1 VWD patients (MAF=0.29) than reported by
dbSNP (MAF=0.38) and the CHARGE consortium
(MAF=0.35). Since the patients were selected on their VWF:Ag
levels, it was expected that the frequency of genetic variants
associated with higher VWF:Ag levels was much lower in our
population.
Alongside the association between rs7978987 and VWF:Ag
levels, this SNP was also significantly and more strongly associated
with VWF:CB. Since VWF:CB is related to the multimer size of
VWF and WPBs contain ultra-large VWF molecules only, this
finding may point to actual involvement of STX2 in WPB
exocytosis. However, this hypothesis can not be further substan-
tiated and should await future research.
One striking finding is the association between genetic variation
in STXBP5 and the bleeding phenotype, as measured by the
bleeding score, in women with type 1 VWD. In the total
population and in men we did not observe this association. This
can be explained by the fact that women experience generally
more challenges to the haemostatic system during life, whereby the
bleeding score in women may be a better reflector of clinically
relevant bleeding tendency, than in men. Indeed, we observed that
the menorraghia item of the bleeding score mainly drives the
association between genetic variation in STXBP5 and the bleeding
score. Nevertheless, the association with bleeding score, which was
assessed by a self-administrated questionnaire, should be inter-
preted with caution and replicated in larger cohorts, since the
number of women per genotype was low.
The association between genetic variation in STX2 and
VWF:Ag levels was independent of blood group. Blood group is
the most important determinant of VWF:Ag levels. The presence
of blood group A and B antigens on VWF molecules leads to a
decreased clearance of VWF molecules. Consequently, individuals
with blood group O have approximately 25% lower VWF plasma
concentrations than individuals with blood group non-O [10].
Furthermore, as blood group O corresponds with lower VWF:Ag
levels, patients diagnosed with type 1 VWD more frequently have
blood group O than non-O. We adjusted our statistical analysis for
blood group, but this did not influence the effect size of the
association. This finding meets our expectations, since we included
only moderate and severe type 1 VWD. Also, genetic variation in
STXBP5 and STX2 may affect the release of VWF molecules,
which is expected to be similar in subjects with blood group O and
in subjects with blood group non-O, rather than the clearance.
In today’s clinical practice diagnosis of type 1 VWD is difficult,
because of the high variability in VWF plasma levels and the
incomplete penetrance of the phenotype. In addition, there is only
a weak association between low VWF:Ag levels and bleeding
symptoms, which are both highly frequent in the general
population. For these reasons it is sometimes hard to distinguish
between physiologically low VWF levels and low VWF levels
because of type 1 VWD [11]. This problem is further underlined
by the fact that a substantial number of individuals with low VWF
levels have no clear family history of bleeding symptoms and no
detectable mutations in the VWF gene (VWF), although is has
been anticipated for a long time that type 1 VWD is caused by
VWF mutations. Three large studies in Europe, the United
Kingdom and Canada showed that only 65% of the type 1 VWD
patients have candidate mutations, meaning that 35% have no
apparent VWF mutations [12,13,14]. Therefore it is likely that
genetic variations in genes other than VWF may contribute to the
variation in VWF levels and bleeding symptoms, as we present in
the current study.
Our study had a few limitations. First, we have not investigated
the combined effect of both SNARE protein gene variations and
VWF mutations on VWF:Ag levels, since we have not performed
VWF gene mutation analysis in our cohort. However, we expect
that mutations in the VWF gene do not interact with polymor-
phisms in STXBP5 and STX2, since STXBP5 is located on a
different chromosome than VWF and STX2 is located more than
120.000 kb from the VWF gene. Therefore, VWF mutations will
be equally distributed across the genotypes. Finally, we are aware
that our sample size is small and that our findings require
replication in larger cohorts of patients with type 1 VWD.
However, our findings are innovative and form the basis for
further research on the role of SNARE protein genes in the clinical
presentation of type 1 VWD.
In conclusion, we have shown that genetic variation in STX2 is
associated with VWF:Ag levels in patients previously diagnosed
with type 1 VWD. In addition, genetic variation in STXBP5 is
associated with the bleeding phenotype in female type 1 VWD
patients. Our findings may explain part of the variation in VWF
levels and bleedings symptoms in patients with type 1 VWD. Also,
alongside known VWF mutations, genetic variations in SNARE
protein genes may help to diagnose individuals with low VWF
levels in the future.
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